Bionovo Announces Third Quarter 2009 Highlights and Financi...(rent liabilities: Accounts payable ...),Health

Date:11/5/2009

rent liabilities: Accounts payable $406 $521 Accrued clinical and costs of other studies 67 73 Accrued compensation and benefits 406 456 Current portion of lease obligations 544 682 Current portion of notes payable 57 - Other current liabilities 772 595 --- --- Total current liabilities 2,252 2,327 Non-current portion of lease obligations 180 545 Non-current portion of notes payable 136 - --- --- Total liabilities 2,568 2,872 ----- ----- Commitments and contingencies Shareholders' equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding - - Common stock $0.0001 par value, 190,000,000 shares authorized, 76,585,550 and 76,363,101 shares outstanding at September 30, 2009 and December 31, 2008, respectively 8 8 Additional paid-in capital 59,852 59,050 Accumulated other comprehensive gain - 24 Accumulated deficit (51,979) (39,450) ------- ------- Total shareholders' equity 7,881 19,632 ----- ------ Total liabilities and shareholders' equity $10,449 $22,
'/>"/>

SOURCE Bionovo, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
2. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
3. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
4. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
5. Bionovo Announces First Quarter 2009 Highlights and Financial Results
6. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
7. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
8. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
9. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
10. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
11. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate